MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4+ T cells in vivo

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-12-10 DOI:10.1080/2162402x.2023.2290799

Thomas V. Guy, Alexandra M. Terry, Helen M. McGuire, Elena Shklovskaya, Barbara Fazekas de St Groth

引用次数: 0

Abstract

There has been growing interest in the role of B cells in antitumour immunity and potential use in adoptive cellular therapies. To date, the success of such therapies is limited. The intrinsic capa...

查看原文本刊更多论文

MHCII 限制表明 B 细胞在体内激活肿瘤特异性 CD4+ T 细胞的能力非常有限

人们越来越关注 B 细胞在抗肿瘤免疫中的作用以及在采纳性细胞疗法中的潜在用途。迄今为止，这种疗法的成功率有限。B细胞的固有能力和免疫功能是导致这种疗法失败的主要原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.